CN114642668B - New pharmaceutical application of latanoprost - Google Patents
New pharmaceutical application of latanoprost Download PDFInfo
- Publication number
- CN114642668B CN114642668B CN202011517930.6A CN202011517930A CN114642668B CN 114642668 B CN114642668 B CN 114642668B CN 202011517930 A CN202011517930 A CN 202011517930A CN 114642668 B CN114642668 B CN 114642668B
- Authority
- CN
- China
- Prior art keywords
- latanoprost
- cardiomyocytes
- pharmaceutically acceptable
- proliferation
- myocardial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 title claims abstract description 48
- 229960001160 latanoprost Drugs 0.000 title claims abstract description 47
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 230000035755 proliferation Effects 0.000 claims abstract description 11
- 230000001737 promoting effect Effects 0.000 claims abstract description 10
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 12
- 238000000338 in vitro Methods 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 18
- 230000002107 myocardial effect Effects 0.000 abstract description 15
- 230000004663 cell proliferation Effects 0.000 abstract description 8
- 208000019622 heart disease Diseases 0.000 abstract description 6
- 208000010125 myocardial infarction Diseases 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 241000700605 Viruses Species 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 210000001742 aqueous humor Anatomy 0.000 description 2
- 238000000975 co-precipitation Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- -1 phenyl-substituted propyl Chemical group 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 241000269333 Caudata Species 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100026893 Troponin T, cardiac muscle Human genes 0.000 description 1
- 101710165323 Troponin T, cardiac muscle Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002253 embryonic cardiomyocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a pharmaceutical application of latanoprost (latanoprost). The application is the application of latanoprost (latanoprost) or pharmaceutically acceptable salt thereof in preparing medicaments for promoting myocardial cell proliferation. Experiments prove that the latanoprost can promote the proliferation of rat myocardial cells. Therefore, the latanoprost can be used for preparing medicaments for promoting myocardial cell proliferation, medicaments for treating or preventing heart diseases and other related fields, and provides a new medicament and treatment idea for treating or preventing heart diseases such as myocardial infarction.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to a novel application of a latanoprost medicine.
Background
Cardiovascular disease has become the first killer threatening human health, and only heart failure patients are 4000 tens of thousands worldwide, and have become the leading cause of human death. It was found that after adult mammalian cardiomyocytes gradually lose proliferation capacity, and once myocardial infarction occurs, the loss of cardiomyocytes is irreversible. About 20-40 million cardiac myocytes in adults can cause about 25% of cardiac myocytes to be lost within hours after myocardial infarction occurs, and the remaining cardiac myocytes have very limited proliferation capacity and are insufficient to restore contractile function of the heart, and the patient eventually dies. To solve this problem, basic transformation studies have mainly involved searching for cardiac stem cells or precursor cells, transplanting them to the myocardial infarction area by inducing differentiation, but lack of sufficiently authentic molecular markers, low transplanting efficiency, limited the use of this technique; the use of reprogramming techniques to transdifferentiate fibroblasts into cardiomyocytes or to supplement lost myocardium by promoting proliferation of endogenous cardiomyocytes. Previous studies have shown that lower vertebrates such as zebra fish, salamander, etc. have a strong ability to regenerate their hearts, and that neonatal rats also have a certain ability to regenerate, mainly through injury-induced cardiomyocyte proliferation, which is lost after adulthood. Adult hearts have previously been considered unable to regenerate, but there is a great deal of evidence that mammalian cardiomyocytes are slowly updated, and studies have found that neonatal cardiomyocytes are derived from existing myocardium. Therefore, more and more scientists are interested in a strategy that induces proliferation of endogenous cardiomyocytes. The search for drugs that induce endogenous cardiomyocyte proliferation is therefore of great interest for the treatment of cardiovascular diseases in humans.
Latanoprost (latanoprost) is a novel phenyl-substituted propyl ester prostacyclin F2a, a selective F2a receptor agonist. It is an inactive but rapidly penetrating substance that hydrolyzes to the active free acid in the cornea and plasma. It can increase the outflow of aqueous humor through the canthus and has small dosage, but can promote the aqueous humor to be filled in large amount, and the liquid medicine can permeate into the supraciliary and suprachoroidal layers of the eyeball, thus having good ocular hypotensive effect. However, there is no report on the induction of endogenous cardiomyocyte proliferation by latanoprost.
Disclosure of Invention
The invention aims to provide a new application of latanoprost (latanoprost) or a pharmaceutically acceptable salt thereof.
The structural formula of the latanoprost (Latanoprast) is shown as formula I, wherein the CAS No. 130209-82-4:
the novel application of the latanoprost or the pharmaceutically acceptable salt thereof provided by the invention is the application of the latanoprost or the pharmaceutically acceptable salt thereof in preparing a product for promoting myocardial cell proliferation.
The cardiomyocytes can be human or mammalian cardiomyocytes. The product may be a pharmaceutical product.
It is another object of the present invention to provide the use of latanoprost (latanoprost) or a pharmaceutically acceptable salt, ester thereof for the preparation of a product for the prevention and/or treatment of cardiovascular diseases. The product may be a pharmaceutical product.
Further, in some embodiments of the invention, the cardiovascular disease may be a heart disease caused by loss, injury or death of cardiomyocytes.
Further, in some embodiments of the invention, the heart diseases described above include, but are not limited to, myocardial infarction, heart failure, cardiomyopathy resulting from other myocardial cell loss, injury or death, and the like.
Products for promoting myocardial cell proliferation prepared by taking latanoprost (latanoprost) or pharmaceutically acceptable salts thereof as active ingredients and products for preventing and/or treating cardiovascular diseases prepared by using the latanoprost (latanoprost) or pharmaceutically acceptable salts thereof also belong to the protection scope of the invention.
If necessary, one or more pharmaceutically acceptable carriers can be added into the medicine; the carrier includes diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption promoters, surfactants, adsorption carriers, lubricants, etc. which are conventional in the pharmaceutical field.
The medicine can be prepared into various forms such as injection, tablet, powder, granule, capsule, oral liquid, ointment, cream, etc.; the medicaments of the various formulations can be prepared according to the conventional method in the pharmaceutical field.
The above medicine can be introduced into organism such as muscle, intradermal, subcutaneous, intravenous, and mucosal tissue by injection, nasal drop, eye drop, permeation, absorption, physical or chemical mediation; or mixed or wrapped with other substances and introduced into the body.
It is still another object of the present invention to provide a method for culturing cardiomyocytes in vitro.
The method for culturing the myocardial cells in vitro provided by the invention comprises the step of adding latanoprost or pharmaceutically acceptable salt thereof into a culture medium containing the myocardial cells.
The final concentration of the latanoprost (latanoprost) or the pharmaceutically acceptable salt thereof in the culture medium is 0.5-2 mu mol/L. The cardiomyocytes can be human or mammalian cardiomyocytes.
The invention also provides a method for promoting myocardial cell proliferation in vitro.
The invention provides a method for promoting myocardial cell proliferation in vitro, which comprises the step of treating myocardial cells with latanoprost (latanoprost) or pharmaceutically acceptable salt thereof.
The concentration of the latanoprost or the pharmaceutically acceptable salt thereof in a treatment system is 0.5-2 mu mol/L. The cardiomyocytes can be human or mammalian cardiomyocytes.
Experiments prove that the latanoprost (latanoprost) can promote the proliferation of rat myocardial cells. Therefore, the latanoprost can be used for preparing medicaments for promoting myocardial cell proliferation, medicaments for treating or preventing heart diseases and other related fields, and provides a new medicament and treatment idea for treating or preventing heart diseases such as myocardial infarction.
Drawings
FIG. 1 is a graph showing the effect of latanoprost (latanoprost) on promoting myocardial cell proliferation in neonatal rats.
Detailed Description
The invention will be further illustrated with reference to the following specific examples, but the invention is not limited to the following examples. The methods are conventional methods unless otherwise specified. The starting materials are available from published commercial sources unless otherwise specified.
The experimental methods used in the following examples are conventional methods unless otherwise specified.
Materials, reagents and the like used in the examples described below are commercially available unless otherwise specified.
The latanoprost (latanoprost) used in the examples below was a DMSO solution of latanoprost (latanoprost). Latanoprest manufacturer TargetMol, cat# T2528.
In the following examples, "FBS" is fetal bovine serum.
The construction method of cTnT-mAG-hGmminin (1/110) virus used in the following examples is as follows:
the cTnT myocardial specificity promoter (shown as sequence 1 in a sequence table) and mAG-hGeminin (1/110) (GenBank: NM_ 015895) are assembled and cloned on a pShuttle vector (Addgene 16402) through pEASY-Uni Seamless Cloning and Assembly Kit (full golden CU 101-01), and then restriction enzyme PmeI is adopted for enzyme digestion, and linearization plasmids are collected; co-transformation of the linearized plasmid with pAdEasy1 DNA (Addgene 16400) into BJ5183 competence, selection of recombinant plasmid and amplification followed by transfection of 293A cells with the recombinant plasmid (7.5X10 day before transfection) 5 The 293A cells were plated in 60mm dishes and cultured in DMEM medium containing 5% fetal calf serum until the number of cells reached 1.0-1.5X10 6 Then, the recombinant plasmid is transfected into cells by a calcium phosphate coprecipitation method, the culture solution containing coprecipitation particles is removed the next day after transfection, PBS buffer solution is used for cleaning, then the cells are divided into 6-well plates (3 ml of DMEM culture solution containing 5% fetal bovine serum is added into each well), and the cells are kept stand for 6 hours to adhere to the walls; after 6 hours agarose was covered for the formation of viral plaques (plaques should form within 10-21 days, with the addition of agarose/DMEM mixtures every 4-5 days or when the medium turns yellow); after obtaining the initial virus, amplifying the initial virus by 2-3 rounds and cesium chloride density gradientThe adenovirus was purified by centrifugation.
Example 1 in vitro test of latanoprost (latanoprost) to promote proliferation of rat cardiomyocytes
(1) Culture of cardiomyocytes in SD rats
Cardiomyocytes from SD rats at birth were isolated and cultured in DMEM high glucose medium (Hyclone) +5% horse serum (GIBCO) at 37℃in a 5% carbon dioxide incubator.
(2) Experimental grouping and processing
Cardiomyocytes from SD rats were isolated, treated with 5% horse serum (GIBCO) +DMEM high-sugar medium (Hyclone) and cytarabine (final concentration 20 umol/L) to inhibit growth of non-cardiomyocytes, infected with cTnT-mAG-hGeminin (1/110) virus (MOI value of virus infection=100) after 48h of cell attachment, and changed to DMEM medium containing 0.5% FBS after 24 hours, and treated by group dosing as follows:
a. experimental group: treatment with latanoprost (latanoprost) (final concentration in medium 2. Mu. Mol/L) was carried out for 24 hours.
b. Blank control group: equivalent DMSO treatment as in experimental group a was added.
(3) Test method
After 24h of treatment of the above 2 groups, nuclei were stained with hoechst fluorochrome, and then photographed with a high content living cell analyzer (Molecular Device), and analyzed for mAG-hGeminin (1/110) -positive cardiomyocyte and total cell count.
(4) Results
The test results are shown in FIG. 1. As can be seen from FIG. 1, mAG-hGemiin (1/110) -positive cardiomyocytes after latanoprost (latanoprost) treatment were increased 3.7-fold compared to the blank control (0.5% FBS+DMSO). Mean±sem; * P < 0.001.
SEQUENCE LISTING
<110> Xin you kang medicine technology (Nanjing) Nanjing Jing Ruikang molecular medicine technology Co., ltd
New use of <120> latanoprost medicine
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 836
<212> DNA
<213> Artificial sequence
<400> 1
tgtagttaat gattaacccg ccatgctact tatctaccag ggtaatgggg atcctctaga 60
actatagcta gaattcgccc ttacgggccc cccctcgagg tcgggataaa agcagtctgg 120
gctttcacat gacagcatct ggggctgcgg cagagggtcg ggtccgaagc gctgccttat 180
cagcgtcccc agccctggga ggtgacagct ggctggcttg tgtcagcccc tcgggcactc 240
acgtatctcc gtccgacggg tttaaaatag caaaactctg aggccacaca atagcttggg 300
cttatatggg ctcctgtggg ggaaggggga gcacggaggg ggccggggcc gctgctgcca 360
aaatagcagc tcacaagtgt tgcattcctc tctgggcgcc gggcacattc ctgctggctc 420
tgcccgcccc ggggtgggcg ccggggggac cttaaagcct ctgcccccca aggagccctt 480
cccagacagc cgccggcacc caccgctccg tgggacgatc cccgaagctc tagagcttta 540
ttgcggtagt ttatcacagt taaattgcta acgcagtcag tgcttctgac acaacagtct 600
cgaacttaag ctgcagaagt tggtcgtgag gcactgggca ggtaagtatc aaggttacaa 660
gacaggttta aggagaccaa tagaaactgg gcttgtcgag acagagaaga ctcttgcgtt 720
tctgataggc acctattggt cttactgaca tccactttgc ctttctctcc acaggtgtcc 780
actcccagtt caattacagc tcttaaggct agagtactta atacgactca ctatag 836
Claims (3)
1. A method of promoting cardiomyocyte proliferation in vitro comprising treating cardiomyocytes with latanoprost or a pharmaceutically acceptable salt thereof; the methods are for non-disease diagnosis and treatment purposes.
2. The method according to claim 1, characterized in that: the concentration of the latanoprost or the pharmaceutically acceptable salt thereof in a treatment system is 0.5-2 mu mol/L.
3. The method according to claim 1 or 2, characterized in that: the cardiomyocyte is a human or mammalian cardiomyocyte.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011517930.6A CN114642668B (en) | 2020-12-21 | 2020-12-21 | New pharmaceutical application of latanoprost |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011517930.6A CN114642668B (en) | 2020-12-21 | 2020-12-21 | New pharmaceutical application of latanoprost |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114642668A CN114642668A (en) | 2022-06-21 |
| CN114642668B true CN114642668B (en) | 2024-04-05 |
Family
ID=81991116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011517930.6A Active CN114642668B (en) | 2020-12-21 | 2020-12-21 | New pharmaceutical application of latanoprost |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114642668B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1684975A (en) * | 2002-08-01 | 2005-10-19 | 阿瑞那制药公司 | Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure |
-
2020
- 2020-12-21 CN CN202011517930.6A patent/CN114642668B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1684975A (en) * | 2002-08-01 | 2005-10-19 | 阿瑞那制药公司 | Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure |
Non-Patent Citations (4)
| Title |
|---|
| Prostaglandin F 2ar induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo;JADINE LAI等;the American Physiological Society;第H2197-H2208页 * |
| Prostaglandin F2a (PGF2a) and the Isoprostane, 8,12-iso-Isoprostane F2a-III, Induce Cardiomyocyte Hypertrophy;Priya Kunapuli等;THE JOURNAL OF BIOLOGICAL CHEMISTRY;第273卷(第35期);第22442-22452页 * |
| Prostaglandin F2a Stimulates Hypertrophic Growth of Cultured Neonatal Rat Ventricular Myocytes*;John W. Adams等;THE JOURNAL OF BIOLOGICAL CHEMISTRY;第271卷(第2期);第1179-1186页 * |
| 余传隆等主编.《中国临床药物大辞典》.中国医学科技出版社,2018,第2677页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114642668A (en) | 2022-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3903796A1 (en) | Cardiomyocyte preparation and preparation method therefor and use thereof | |
| JP6868307B2 (en) | Composition for prevention or treatment of liver fibrosis containing exosomes derived from adipose stem cells as an active ingredient | |
| CN109294980B (en) | Application of rhodiola rosea and salidroside in directional differentiation of stem cells into myocardial-like cells | |
| KR20090033328A (en) | Immune privileged and modulatory progenitor cells | |
| CN111374975A (en) | Medicinal application of harmine | |
| CN116270451A (en) | Fresh mesenchymal stem cell injection and preparation method thereof | |
| Quan et al. | Thymosin β4 promotes the survival and angiogenesis of transplanted endothelial progenitor cells in the infarcted myocardium | |
| WO2022135278A1 (en) | Novel application of azd3965 medicine | |
| CN114642668B (en) | New pharmaceutical application of latanoprost | |
| CN112494494B (en) | Novel pharmaceutical application of BML-28-4 | |
| CN114642662B (en) | Pharmaceutical use of MK-5046 | |
| CN114652717B (en) | Pharmaceutical application of naphazoline hydrochloride | |
| CN113842389B (en) | Pharmaceutical composition for preventing and/or treating cardiovascular diseases | |
| CN112516146B (en) | Novel medicinal application of AZ191 | |
| CN112603914B (en) | New application of phenylephrine hydrochloride medicament | |
| CN112587530B (en) | Novel pharmaceutical application of Baricitinib | |
| CN114712367A (en) | New pharmaceutical application of VO-OHIPIC trihydrate | |
| CN111686124A (en) | Application of miR-486-3p in preparation of product for treating neuroinflammation caused by SAH (neuroinflammation) | |
| CN112451529A (en) | New pharmaceutical application of Kb-NB 142-70 | |
| CN112587513A (en) | New application of noradrenaline medicine | |
| CN115869302A (en) | Application of composition containing GSDME agonist and GSDMD agonist in preparation of pancreatic tumor cell apoptosis drug | |
| CN115154469A (en) | Application of rimazepam or pharmaceutically acceptable salt thereof in preparation of medicament for preventing or treating obesity | |
| CN116421729A (en) | Function and application of adipocyte enhanced binding protein 1 in treatment of tissue fibrosis | |
| CN100430412C (en) | Nucleic acid molecule RTN4BSR6 and application for preparation of anti-cancer drugs | |
| CN100503825C (en) | Nucleic acid molecule RTN4BSR4 and its application in preparing anticancer medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |